Matching trials
384 results
- ROSEComplete statistical analysis of the ROSE phase 3 trial of early neuromuscular blockade versus no routine early neuromuscular blockade in acute respiratory distress syndrome, including trial design, the primary mortality endpoint, Wald…
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- RTOG 0825Independent statistical analysis of RTOG 0825, a randomized phase 3 trial of temozolomide and radiation therapy with or without bevacizumab in patients with newly diagnosed glioblastoma.
- RUXCOVIDIndependent statistical analysis of the phase 3 RUXCOVID trial of ruxolitinib versus placebo in patients with COVID-19 associated cytokine storm, including the primary composite endpoint, secondary outcomes, statistical methods, safety, and interpretation.
- RxPONDERIndependent statistical analysis of the randomized phase 3 RxPONDER trial, including its invasive disease-free survival endpoint, Cox proportional-hazards analyses, menopausal-status interaction, post-hoc distant relapse-free survival results, safety, and statistical interpretation.
- S-TRACIndependent statistical analysis of the S-TRAC phase 3 trial of sunitinib versus placebo in patients at high risk of recurrent renal cell cancer, including disease-free survival, overall survival, trial design, Cox modeling,…
- SAILINGComplete statistical analysis of the SAILING phase 3 trial comparing GSK1349572 (dolutegravir) with raltegravir in antiretroviral-experienced, integrase inhibitor-naive adults with HIV infection, including its non-inferiority design, Cochran-Mantel-Haenszel analysis, risk difference, confidence interval,…
- SALSAIndependent statistical analysis of the phase 3 SALSA trial of switching to dolutegravir/lamivudine fixed-dose combination from a current antiretroviral regimen in virologically suppressed adults with HIV-1 infection.
- SCOREDIndependent statistical analysis of SCORED (NCT03315143), a randomized phase 3 trial of sotagliflozin versus placebo in participants with type 2 diabetes and moderate renal impairment at cardiovascular risk. Includes the primary cardiovascular…
- SELECTAn independent statistical analysis of the SELECT phase 3 trial of semaglutide versus placebo in patients with overweight or obesity, including trial design, the primary time-to-event endpoint, Cox proportional-hazards analysis, and interpretation.
- SELECTComplete statistical analysis of SELECT (NCT01321554), the phase 3 randomized, double-blind, placebo-controlled trial of lenvatinib in 131I-refractory differentiated thyroid cancer, including progression-free survival, statistical methodology, safety, and interpretation.
- SEQUOIAIndependent statistical analysis of the phase 3 SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, including its progression-free survival analysis and statistical…
- SERAPHINIndependent statistical analysis of SERAPHIN, the randomized phase 3 trial of macitentan in symptomatic pulmonary arterial hypertension, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, and interpretation.
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…
- SHIFTComplete statistical analysis of SHIFT, a randomized phase 3 trial evaluating ivabradine versus placebo in patients with chronic heart failure, including Cox proportional-hazards methods, hazard ratios, confidence intervals, p-values, safety, and statistical…
- SIGNIFYIndependent statistical analysis of SIGNIFY (NCT02446990), a randomized phase 3 trial of ivabradine versus placebo in patients with stable coronary artery disease without clinical heart failure, including Cox proportional-hazards analyses and interpretation…
- SINGLEComplete statistical analysis of the SINGLE phase 3 trial comparing dolutegravir plus abacavir/lamivudine with Atripla in HIV-1 infection, including the Week 48 primary endpoint, later virologic suppression analyses, CD4 outcomes, non-inferiority methodology,…
- SKYSCRAPER-02Independent statistical analysis of SKYSCRAPER-02, a randomized phase 3 trial of tiragolumab plus atezolizumab with carboplatin and etoposide versus placebo plus atezolizumab with carboplatin and etoposide in untreated extensive-stage small cell lung…
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- SOCRATESIndependent statistical analysis of the SOCRATES phase 3 trial of ticagrelor versus acetylsalicylic acid after acute ischaemic stroke or transient ischaemic attack, including endpoint definitions, Cox and logistic regression methods, efficacy results,…
- SOFTIndependent statistical analysis of the SOFT phase 3 trial of tamoxifen, tamoxifen plus ovarian function suppression, and exemestane plus ovarian function suppression in premenopausal women with hormone-responsive breast cancer.
- SOLAR-1Independent statistical analysis of the SOLAR-1 phase 3 trial of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer that progressed on or after aromatase inhibitor treatment.
- SOLEComplete statistical analysis of the SOLE phase 3 trial of continuous versus intermittent letrozole in postmenopausal women with hormone receptor-positive, lymph node-positive, early-stage breast cancer after prior hormone therapy.
- SOLO1Complete statistical analysis of SOLO1, a randomized phase 3 trial of olaparib maintenance monotherapy versus placebo in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.
- SOLOIST-WHFIndependent statistical analysis of SOLOIST-WHF (NCT03521934), evaluating sotagliflozin versus placebo in participants with type 2 diabetes and worsening heart failure. Includes trial design, registered endpoints, Cox, ANCOVA and MMRM methodology, reported results,…
- SONARIndependent statistical analysis of the phase 3 SONAR trial of atrasentan versus placebo in diabetic nephropathy, including the composite renal endpoint, hazard ratios, confidence intervals, p-values, trial design, and statistical methodology.
- SOPHIAIndependent statistical analysis of the SOPHIA phase 3 trial of margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer, including its randomized design, time-to-event endpoints, hazard ratios, confidence intervals,…
- SPARTANIndependent statistical analysis of the phase 3 SPARTAN trial of apalutamide versus placebo in men with non-metastatic castration-resistant prostate cancer, including metastasis-free survival, time to metastasis, progression-free survival, statistical methodology, safety, and…
- SPLASHIndependent statistical analysis of the phase 3 SPLASH trial evaluating [Lu-177]-PNT2002 in metastatic castration-resistant prostate cancer, including randomized design, radiographic progression-free survival, hazard-ratio methodology, and statistical interpretation.
- SPOTLIGHTComplete statistical analysis of the randomized phase 3 SPOTLIGHT trial of zolbetuximab plus chemotherapy versus placebo plus chemotherapy in adults with gastric or gastroesophageal junction adenocarcinoma, including progression-free survival, overall survival, response,…
- SPRING-2Independent statistical analysis of the SPRING-2 phase 3 trial comparing dolutegravir 50 mg once daily with raltegravir 400 mg twice daily for HIV-1 infection, including its non-inferiority design, stratified Cochran-Mantel-Haenszel analysis, confidence…
- STARSCAPEIndependent statistical analysis of the STARSCAPE phase 3 trial of zinpentraxin alfa in idiopathic pulmonary fibrosis, including trial design, endpoints, randomized efficacy analysis, time-to-event methods, safety, limitations, and statistical interpretation.
- STELLARIndependent statistical analysis of the phase 3 STELLAR trial of sotatercept plus background PAH therapy versus placebo plus background PAH therapy in pulmonary arterial hypertension, including trial design, endpoints, nonparametric analyses, hazard…
- STEP 1Complete statistical analysis of STEP 1 (NCT03548935), a randomized phase 3 trial of semaglutide 2.4 mg versus placebo in people with overweight or obesity, including its ANCOVA and logistic-regression analyses, effect estimates,…
- STEP 2Complete statistical analysis of STEP 2, the randomized phase 3 trial of semaglutide in people with type 2 diabetes and overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression,…
- STEP 3Complete statistical analysis of STEP 3 (NCT03611582), a phase 3 randomized trial evaluating semaglutide versus placebo for weight reduction in people with overweight or obesity, including endpoint definitions, ANCOVA, MMRM, logistic regression,…
- STEP 4Independent statistical analysis of STEP 4 (NCT03548987), a randomized phase 3 trial evaluating change in body weight with semaglutide 2.4 mg versus placebo in people with overweight or obesity.
- STEP 5Complete statistical analysis of the STEP 5 phase 3 trial of semaglutide versus placebo in adults with overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression, confidence intervals, and…
- STEP 8Complete statistical analysis of STEP 8, a randomized phase 3 trial comparing semaglutide 2.4 mg with liraglutide 3.0 mg in people living with overweight or obesity, including the registered body-weight endpoint, ANCOVA…
- STEP-HFpEFIndependent statistical analysis of the phase 3 STEP-HFpEF trial of semaglutide in people living with heart failure and obesity, including trial design, ANCOVA methodology, primary endpoints, confidence intervals, p-values, safety, and interpretation.
- STRENGTHComplete statistical analysis of the STRENGTH phase 3 trial of Epanova versus corn oil control in high cardiovascular risk patients with hypertriglyceridemia, including trial design, MACE, Cox proportional-hazards analysis, secondary endpoints, safety,…
- STRIVEComplete statistical analysis of the STRIVE phase 3 trial of erenumab for migraine prevention, including randomized trial design, primary and secondary endpoint analyses, mixed-effects models, Cochran-Mantel-Haenszel testing, multiplicity, and safety.
- SUNLIGHTIndependent statistical analysis of the phase 3 SUNLIGHT trial of trifluridine/tipiracil with and without bevacizumab in refractory metastatic colorectal cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, and statistical interpretation.
- SURMOUNT-3Independent statistical analysis of the phase 3 SURMOUNT-3 trial of tirzepatide in participants with obesity or overweight after a lifestyle weight loss program, including trial design, primary endpoints, reported estimates, statistical methods,…
- SURMOUNT-OSAIndependent statistical analysis of SURMOUNT-OSA, a randomized phase 3 trial of tirzepatide in participants with obstructive sleep apnea and obesity, including AHI results, ANCOVA, logistic regression, confidence intervals, and safety.
- SURPASS-3Complete statistical analysis of SURPASS-3, a randomized phase 3 trial comparing tirzepatide with insulin degludec in participants with type 2 diabetes, including HbA1c, body weight, fasting serum glucose, treatment satisfaction, statistical methodology,…
- SURPASS-4Independent statistical analysis of SURPASS-4, a randomized phase 3 trial of once-weekly tirzepatide versus once-daily insulin glargine in participants with type 2 diabetes and increased cardiovascular risk.
- SURPASS-5Complete statistical analysis of SURPASS-5, a randomized phase 3 trial of tirzepatide versus placebo in participants with type 2 diabetes inadequately controlled on insulin glargine with or without metformin.
- SUSTAIN-3Independent statistical analysis of SUSTAIN-3, the randomized phase 3 trial comparing once-weekly semaglutide 1.0 mg with exenatide ER 2.0 mg in subjects with type 2 diabetes receiving 1–2 oral antidiabetic drugs.
- SUSTAIN-7Independent statistical analysis of the SUSTAIN-7 phase 3 trial comparing semaglutide with dulaglutide as add-on to metformin in subjects with type 2 diabetes, including mixed-effects modeling, non-inferiority and superiority testing, confidence intervals,…